Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers

Mark A. Malesker, Syed M. Mohiuddin, Christopher J. Destache, Anne Stoysich, Richard R. Dean, Daniel E. Hilleman, Michael H. Sketch

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The pharmacokinetics and tolerance of actisomide (SC-36602) were determined following intravenous doses of 2.1, 4.2, and 8.4 mg/kg infused over five hours. Plasma concentrations observed in the low-dose group (2.1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis. The following pharmacokinetic parameters were obtained in the medium-dose (4.2 mg/kg) and high-dose (8.4 mg/kg) groups, respectively: Peak plasma concentration 4.25 ± 0.26 and 7.81 ± 0.31 μg/mL; area under the plasma concentration versus time curve 19.79 ± 2.96 and 39.81 ±7.05 h • μg/mL; elimination rate constant of the beta phase 0.105 ± 0.77 and 0.093 ± 0.009 h−1; and half-life 8.85 ± 4.61 and 7.51 ± 0.69 h. Left ventricular ejection fraction decreased by 10, 11, and 16 percent in the low-, medium-, and high-dose groups, respectively. Heart rate was not altered during the low-dose infusion. At the medium- and high-dose levels, resting peak heart rate increased by 18 and 27 percent, respectively. Systolic and diastolic blood pressures were not significantly changed in any of the dose groups. Changes in electrocardiographic intervals for the three dose groups were not significant except at the highest dose where an average 20 percent increase in the QRS interval was seen. Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group. Further studies are warranted to more fully characterize the pharmacokinetic profile and therapeutic potential of actisomide.

Original languageEnglish
Pages (from-to)231-234
Number of pages4
JournalAnnals of Pharmacotherapy
Volume25
Issue number3
DOIs
StatePublished - 1991

Fingerprint

Healthy Volunteers
Pharmacokinetics
Heart Rate
Blood Pressure
Paresthesia
Dizziness
Stroke Volume
Half-Life
Limit of Detection
SC 36602
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. / Malesker, Mark A.; Mohiuddin, Syed M.; Destache, Christopher J.; Stoysich, Anne; Dean, Richard R.; Hilleman, Daniel E.; Sketch, Michael H.

In: Annals of Pharmacotherapy, Vol. 25, No. 3, 1991, p. 231-234.

Research output: Contribution to journalArticle

@article{98d25c1c2838469a97b4cbb72b4e24a8,
title = "Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers",
abstract = "The pharmacokinetics and tolerance of actisomide (SC-36602) were determined following intravenous doses of 2.1, 4.2, and 8.4 mg/kg infused over five hours. Plasma concentrations observed in the low-dose group (2.1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis. The following pharmacokinetic parameters were obtained in the medium-dose (4.2 mg/kg) and high-dose (8.4 mg/kg) groups, respectively: Peak plasma concentration 4.25 ± 0.26 and 7.81 ± 0.31 μg/mL; area under the plasma concentration versus time curve 19.79 ± 2.96 and 39.81 ±7.05 h • μg/mL; elimination rate constant of the beta phase 0.105 ± 0.77 and 0.093 ± 0.009 h−1; and half-life 8.85 ± 4.61 and 7.51 ± 0.69 h. Left ventricular ejection fraction decreased by 10, 11, and 16 percent in the low-, medium-, and high-dose groups, respectively. Heart rate was not altered during the low-dose infusion. At the medium- and high-dose levels, resting peak heart rate increased by 18 and 27 percent, respectively. Systolic and diastolic blood pressures were not significantly changed in any of the dose groups. Changes in electrocardiographic intervals for the three dose groups were not significant except at the highest dose where an average 20 percent increase in the QRS interval was seen. Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group. Further studies are warranted to more fully characterize the pharmacokinetic profile and therapeutic potential of actisomide.",
author = "Malesker, {Mark A.} and Mohiuddin, {Syed M.} and Destache, {Christopher J.} and Anne Stoysich and Dean, {Richard R.} and Hilleman, {Daniel E.} and Sketch, {Michael H.}",
year = "1991",
doi = "10.1177/106002809102500301",
language = "English",
volume = "25",
pages = "231--234",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "3",

}

TY - JOUR

T1 - Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers

AU - Malesker, Mark A.

AU - Mohiuddin, Syed M.

AU - Destache, Christopher J.

AU - Stoysich, Anne

AU - Dean, Richard R.

AU - Hilleman, Daniel E.

AU - Sketch, Michael H.

PY - 1991

Y1 - 1991

N2 - The pharmacokinetics and tolerance of actisomide (SC-36602) were determined following intravenous doses of 2.1, 4.2, and 8.4 mg/kg infused over five hours. Plasma concentrations observed in the low-dose group (2.1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis. The following pharmacokinetic parameters were obtained in the medium-dose (4.2 mg/kg) and high-dose (8.4 mg/kg) groups, respectively: Peak plasma concentration 4.25 ± 0.26 and 7.81 ± 0.31 μg/mL; area under the plasma concentration versus time curve 19.79 ± 2.96 and 39.81 ±7.05 h • μg/mL; elimination rate constant of the beta phase 0.105 ± 0.77 and 0.093 ± 0.009 h−1; and half-life 8.85 ± 4.61 and 7.51 ± 0.69 h. Left ventricular ejection fraction decreased by 10, 11, and 16 percent in the low-, medium-, and high-dose groups, respectively. Heart rate was not altered during the low-dose infusion. At the medium- and high-dose levels, resting peak heart rate increased by 18 and 27 percent, respectively. Systolic and diastolic blood pressures were not significantly changed in any of the dose groups. Changes in electrocardiographic intervals for the three dose groups were not significant except at the highest dose where an average 20 percent increase in the QRS interval was seen. Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group. Further studies are warranted to more fully characterize the pharmacokinetic profile and therapeutic potential of actisomide.

AB - The pharmacokinetics and tolerance of actisomide (SC-36602) were determined following intravenous doses of 2.1, 4.2, and 8.4 mg/kg infused over five hours. Plasma concentrations observed in the low-dose group (2.1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis. The following pharmacokinetic parameters were obtained in the medium-dose (4.2 mg/kg) and high-dose (8.4 mg/kg) groups, respectively: Peak plasma concentration 4.25 ± 0.26 and 7.81 ± 0.31 μg/mL; area under the plasma concentration versus time curve 19.79 ± 2.96 and 39.81 ±7.05 h • μg/mL; elimination rate constant of the beta phase 0.105 ± 0.77 and 0.093 ± 0.009 h−1; and half-life 8.85 ± 4.61 and 7.51 ± 0.69 h. Left ventricular ejection fraction decreased by 10, 11, and 16 percent in the low-, medium-, and high-dose groups, respectively. Heart rate was not altered during the low-dose infusion. At the medium- and high-dose levels, resting peak heart rate increased by 18 and 27 percent, respectively. Systolic and diastolic blood pressures were not significantly changed in any of the dose groups. Changes in electrocardiographic intervals for the three dose groups were not significant except at the highest dose where an average 20 percent increase in the QRS interval was seen. Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group. Further studies are warranted to more fully characterize the pharmacokinetic profile and therapeutic potential of actisomide.

UR - http://www.scopus.com/inward/record.url?scp=0025890087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025890087&partnerID=8YFLogxK

U2 - 10.1177/106002809102500301

DO - 10.1177/106002809102500301

M3 - Article

VL - 25

SP - 231

EP - 234

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 3

ER -